Katherine Louise Jones

This inventor holds 10 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 6 EPO patents. Top assignees: Glaxosmithkline LLC, Glaxosmithkline Intellectual Property Development Limited, Glaxogrouplimited. Active years: 2009-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Katherine Louise Jones. Retrieved from https://idiyas.com/inventor/katherine-louise-jones

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 8)

% Patents Active = 20.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 15)

Average Co-Inventor Count = 3.8

ph-index = 3

Forward Citations = 74(Granted Patents)

Company Filing History:

Glaxosmithkline Intellectual Property Development Limited

Smithkline Beecham Corporation

patents

Years Active: 2009-2021

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11053212 - Benzimidazole derivatives as bromodomain inhibitors (2021-07-06),

2. 10442786 - Benzimidazole derivatives as bromodomain inhibitors (2019-10-15),

3. 9861627 - 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1 H-imidazo[4,5-C]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor (2018-01-09),

4. 9610284 - 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor (2017-04-04),

5. 9416130 - 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1 H-imidazo[4,5-C]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor (2016-08-16),

6. 9315487 - Tetrahydroquinoline derivatives useful as bromodomain inhibitors (2016-04-19),

7. 9067936 - 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1 H-imidazo[4,5-C]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor (2015-06-30),

8. 8846709 - 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1H-imidazo[4,5-C]quinoline derivatives (2014-09-30),

9. 8163743 - 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases (2012-04-24),

10. 7572790 - Biphenyl carboxylic amide p38 kinase inhibitors (2009-08-11),

Title: Katherine Louise Jones: Innovator in Bromodomain Inhibitors

Introduction

Katherine Louise Jones is a prominent inventor based in Stevenage, GB. She has made significant contributions to the field of medicinal chemistry, particularly in the development of novel therapeutic compounds. With a total of 10 patents to her name, her work focuses on innovative solutions for treating autoimmune and inflammatory diseases, as well as cancers.

Latest Patents

Among her latest patents are the benzimidazole derivatives as bromodomain inhibitors. These compounds, defined by specific formulas, have been found to inhibit the binding of the BET family of bromodomain proteins to acetylated lysine residues. This inhibition may have therapeutic applications, particularly in the treatment of conditions such as rheumatoid arthritis and various cancers.

Career Highlights

Katherine has worked with notable companies in the pharmaceutical industry, including GlaxoSmithKline LLC and GlaxoSmithKline Intellectual Property Development Limited. Her experience in these organizations has allowed her to advance her research and contribute to the development of important medical therapies.

Collaborations

Katherine has collaborated with esteemed colleagues in her field, including Emmanuel Hubert Demont and Robert J Watson. These partnerships have further enriched her research and innovation efforts.

Conclusion

Katherine Louise Jones stands out as a dedicated inventor whose work in bromodomain inhibitors holds promise for advancing therapeutic options in medicine. Her contributions continue to impact the field positively.

Profile summary based on public USPTO records.